HAUSMAN DIANA 4

4 · Zymeworks Inc. · Filed Dec 4, 2020

Form 4

Period: 2020-12-04

Chief Medical Officer

Transactions

Exercise/Conversion
Common Shares
2020-12-04$9.82/sh+2,850$27,987→ 6,568 total
Exercise/Conversion
Stock Option (Right to Buy)
2020-12-04−2,850→ 68,028 total
Exercise: $9.82From: 2018-06-12Exp: 2027-06-12→ Common Shares (2,850 underlying)
Sale
Common Shares
2020-12-04$55.12/sh−6,032$332,476→ 3,718 total
Exercise/Conversion
Stock Option (Right to Buy)
2020-12-04−3,182→ 47,673 total
Exercise: $11.84From: 2019-03-19Exp: 2028-03-18→ Common Shares (3,182 underlying)
Exercise/Conversion
Common Shares
2020-12-04$11.84/sh+3,182$37,675→ 9,750 total

Holdings

Footnotes (3)

[F1]Pursuant to a 10b5-1 plan.
[F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $55.00 to $55.38, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 4, 2020 at each separate price.
[F3]Stock options vest as follows: (i) 25% of underlying shares on first anniversary of grant date and (ii) remainder of underlying shares in 36 equal monthly installments on last day of month following the first anniversary of grant date. The grant date was ten years before the listed expiration date.

Documents

1 file